Galleri Test
Multi-cancer early detection blood test screening for 50+ cancer types
Device · OtherCompany source
Company profile
About Grail
GRAIL is a healthcare company focused on alleviating the global burden of cancer through early detection. Founded in 2016 as a spinout from Illumina, GRAIL pioneered the multi-cancer early detection (MCED) category after discovering that cell-free DNA from cancer could be detected in blood samples. The company's flagship product, the Galleri test, is a first-of-its-kind blood test capable of screening for signals from more than 50 types of cancer before symptoms appear, including many cancers that lack recommended screening tests today. GRAIL combines the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to revolutionize cancer screening. The company operates CAP-accredited, CLIA-certified laboratory facilities exceeding 170,000 square feet with capacity to support multiple years of growth. GRAIL serves healthcare systems, providers, payers, and individual patients primarily in the United States and United Kingdom. The company has enrolled over 380,000 participants across its unprecedented clinical program, generating more than 300 scientific publications and presentations. GRAIL's mission is to detect cancer early when it can be cured, fundamentally changing the cancer continuum from late-stage diagnosis to early intervention.
Company description Grail official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Grail?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancers without existing routine screening options
- Early-stage cancers
- Esophageal cancer
- Multi-cancer screening covering 50+ cancer types
Who it serves
- Government/Veterans Affairs
- Health Systems
- Individual Patients
- Life Insurance
- Payers
- Providers
Deployment & integration
Other deployment with recorded integration context.
Recorded integration context: Epic.
Geographic context
MarketsUnited Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA Premarket Approval Application submitted January 2026; ASCO 2026 presentations of NHS-Galleri and PATHFINDER 2 results (May-June 2026); Epic EHR integration announced April 2026; $110M equity financing with Samsung entities June 2026; Q1 2026 financial results reported May 2026
Partnerships
Recorded partners
- AstraZeneca
- Epic Systems
- John Hancock
- Providence Health System
- Samsung entities
- U.S. Department of Veterans Affairs
- UK National Health Service (NHS)
- Veterans Health Foundation
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Factors That Influence Genetic Counselors' Professional Identity-A Qualitative Study.Journal of genetic counseling · Aug 1, 2026
Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study.The Lancet regional health. Europe · Jul 1, 2026
Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England.British journal of cancer · Jul 1, 2026
Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches.Cancer prevention research (Philadelphia, Pa.) · Jun 1, 2026
Modeled sojourn time and sensitivity for detecting preclinical cancers retrospectively by a multi-cancer early detection test.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · May 4, 2026
Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3.Cancer · Apr 15, 2026
Clinical validation
Clinical-trial records
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical TrialNCT05611632 · Sponsor · ACTIVE NOT RECRUITING
Gabapentin to Reduce Alcohol and Improve Viral Load SuppressionNCT05443555 · Mentioned · ACTIVE NOT RECRUITING
AI-based Model for Rehabilitation Engagement and Motor Performance Evaluation in Pediatric PatientsNCT06993389 · Mentioned · COMPLETED
Dynamic Balance in Unilateral Transtibial Amputees Following Virtual Reality Versus Conventional RehabilitationNCT06424249 · Mentioned · RECRUITING
AI-based Model for Rehabilitation Engagement and Motor Performance Evaluation in Pediatric Patients: A Pilot StudyNCT07664033 · Mentioned · NOT YET RECRUITING
Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early DetectionNCT05481697 · Mentioned · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
85.0% sensitivity for esophageal cancer
Overall sensitivity across stages (12.5% stage I, 64.7% stage II, 94.7% stage III, 100% stage IV)
Substantial reduction in stage IV cancer diagnoses
NHS-Galleri trial results presented at ASCO 2026
Reduction in late-stage diagnoses by more than half
Modeling study published in Cancer Epidemiology, Biomarkers & Prevention
UK National Health Service (NHS)
NHS-Galleri trial - world's first randomized controlled trial of multi-cancer early detection test with 140,000 participants
Substantial reduction in Stage IV cancer diagnoses demonstrated
John Hancock
First life insurance carrier to offer access to GRAIL's multi-cancer early detection test to customers
U.S. Department of Veterans Affairs
Collaboration with Veterans Health Foundation to evaluate the Galleri test for veterans at higher risk for cancer
Providence Health System
First healthcare system to offer Galleri multi-cancer early detection test to patients
Kevin McFarland (Firefighter)
Early detection of stage I esophageal cancer in asymptomatic firefighter through multi-cancer early detection screening offered by fire department
Stage I esophageal cancer detected and treated with minimally invasive surgery without requiring chemo radiation, providing good chance at long-term survival
Ohio State University James Comprehensive Cancer Center
Treatment of early-stage esophageal cancer detected by Galleri test
Stage I detection enabled minimally invasive surgery without chemo radiation
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Grail
Recent articles published on Grail's official website.
Not All MCED Tests are Created Equal: The Realities of MCED Test Development and Validation
Read on GrailWhy Finding Cancers Before It’s Too Late Matters More Than Ever
Read on GrailGRAIL Update on the Accelerated Implementation of Multi-Cancer Early Detection Technology by NHS England
Read on GrailMaking Sense of the Numbers: Interpreting Multi-Cancer Early Detection Test Performance
Read on GrailThe NHS-Galleri trial: What to expect in 2026 from the world’s first randomized controlled trial of a Multi-Cancer Early Detection test, Galleri®
Read on Grail07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.